Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Biotech

Guardant Health

Guardant Health raises $360M Series E at $2.15B valuation

$360M
Total Raised
Series E
Latest Round
2012
Founded
1000+
Employees
Redwood City, CA
Updated May 31, 2018
1 min read

Quick Facts

Valuation
$2.15B
Latest Round Size
$360M
Latest Round Date
May 2018

Guardant Health: Series E Funding Round

Guardant Health has successfully raised $360M in Series E funding, reaching a valuation of $2.15B.

Company Overview

Blood-based cancer detection and monitoring

Funding Details

The Series E round was led by SoftBank Vision Fund, with participation from OrbiMed.

Company Information

  • Headquarters: Redwood City, CA
  • Founded: 2012
  • Employees: 1000+
  • Category: Biotech

Investment

Guardant Health plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • SoftBank Vision Fund: Verified investor in Series E
  • OrbiMed: Verified investor in Series E

Key Investors

SoftBank Vision Fund
Lead Investor
Verified investor in Series E
OrbiMed
Investor
Verified investor in Series E

Topics

verified(3079)real-funding(3079)guardant-healthbiotechseries-eredwood-city

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$250M